[O-33] 治療創薬、再生医療2

[O-33-1] Efficacy and safety of satralizumab (SA237) as add-on therapy for NMOSD: Results from Phase 3 study

山村 隆¹, Ingo Kleiter², 藤原 一男³, Jacqueline Palace⁴, Greenberg Benjamin⁵, Beata Zakrzewska-pniewska⁶, Francesco Patti⁷, Tsai Ching-piao⁸, Albert Saiz⁹, 寺田 悠介¹⁰, 河田 祐一¹⁰, Padraig Wright¹¹, Jerome De Seze¹² (1.国立精神・神経医療研究センター 免疫研究部, 2.Department of Neurology, Ruhr University Bochum, Bochum, Germany, 3.福島県立医科大学　多発性硬化症治療学講座、一般財団法人脳神経疾患研究所　多発性硬化症・視神経脊髄炎センター, 4.Department of Clinical Neurology, John Radcliffe Hospital, Oxford, United Kingdom, 5.Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA, 6.Department of Neurology, Warsaw Medical University, Warsaw, Poland, 7.Department G.F. Ingrassia-section of Neurosciences, University of Catania, Catania, Italy, 8.Neurological Institute, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan, 9.Service of Neurology, Hospital Clinic and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, 10.中外製薬株式会社, 11.Chugai Pharma Europe, 12.Department of Neurology, Hôpital de Hautepierre, Strasbourg Cedex, France)